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 Diabetes mellitus is a group of diseases characterized by chronic 
hyperglycaemia and disturbances of carbohydrate, fat and protein metabolism 
resulting from defects in insulin secretion, insulin action, or both. Despite the 
availability of exogenous insulin, insulin analogues and other pharmacological 
agents, a lifetime of good glycaemic control remains an elusive goal for a 
substantial majority of diabetics. 
 Cell-based approaches are emerging strategies for diabetes treatment. 
Differentiation of stem/progenitor cells in beta cells appears promising, while the 
efficacy of a simpler approach of modifying autologous adult somatic cells is 
uncertain. Our approach was to electroporate autologous primary hepatocytes 
with a plasmid construct encoding human proinsulin cDNA driven by a 
bifunctional promoter comprising the human metallothionein IIA promoter linked 
to a single copy of the carbohydrate response element (ChoRE). 
 Engineered hepatocytes were then transplanted into streptozotocin-
induced diabetic cynomolgus macaques. Daily fasting blood glucose and insulin 
requirements were monitored along with biochemical tests of liver and renal 
function. Intravenous glucose tolerance tests (IVGTT) were performed at 3 
distinct stages of the study. 
 In vitro studies confirmed the transfected hepatocytes had regulated 
insulin secretion in response to glucose and zinc. Diabetes was reliably induced 
in monkeys with a dose of 875 mg/m2 with mild derangement of liver and renal 
 vi
function. Diabetic monkeys transplanted with transfected hepatocytes had lower 
fasting blood glucose levels compared to controls and did not require exogenous 
insulin therapy to achieve this.   
Treated animals had post-transplant IVGTT curves for glucose similar to 
their pre-diabetic state but control animals had post-transplant IVGTT curves 
similar to their diabetic state. The area under the curve (AUC) for insulin was 
higher in the post-transplant state compared to the diabetic state in the treated 
monkeys although the curves themselves did not return to the prediabetic state. 
In controls, insulin AUC was lower post-transplant compared to the diabetic state. 
We have shown that hepatocytes transfected with the said plasmid 
construct were able to achieve regulated insulin secretion. When transplanted 
into diabetic monkeys, these engineered hepatocytes were able to partially 
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CHAPTER 1: INTRODUCTION 
 
1.1 Diabetes Mellitus 
 
1.1.1  Definition and Classification of Diabetes Mellitus 
Diabetes mellitus is a disorder of carbohydrate, fat and protein metabolism 
characterized by chronic hyperglycaemia. It results from defects in insulin 
secretion, insulin action, or both. The World Health Organization recognizes 
three main forms of diabetes: type 1, type 2 and gestational diabetes (occurring 
during pregnancy) [1].  
Type 1 diabetes, previously called insulin-dependent diabetes mellitus 
(IDDM) or juvenile-onset diabetes, is caused by autoimmune destruction of the 
insulin-producing beta cells in the pancreatic islets of Langerhans leading to an 
absolute deficiency of insulin. This type comprises up to 10% of total cases of 
diabetes in North America and Europe. Type 2 diabetes, the most common form, 
was previously called non-insulin-dependent diabetes mellitus (NIDDM) or adult-
onset diabetes. It results from a combination of insulin resistance, whereby 
muscle, liver and fat cells do not use insulin properly, and beta cell dysfunction, 
leading to relative insulin deficiency [2]. As the need for insulin rises, the 
pancreas gradually loses its ability to produce it and ‘burns out’. Gestational 
diabetes develops in some women during the late stages of pregnancy. It is 
similar to type 2 diabetes in that it involves insulin resistance - the hormones of 
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pregnancy cause insulin resistance in women genetically predisposed to 
developing this condition. 
Diabetes can cause many complications. Acute complications such as 
hypoglycaemia, ketoacidosis or nonketotic hyperosmolar coma may occur if the 
disease is not adequately controlled. Serious long term complications are caused 
by chronic hyperglycaemia which damages nerves and blood vessels. This leads 
to heart disease, stroke, chronic renal failure (diabetic nephropathy is the main 
cause of end-stage renal disease in developed world adults), peripheral vascular 
disease, retinal damage leading to blindness, neuropathy, and microvascular 
damage which may cause erectile dysfunction and poor healing. Peripheral 
vascular disease, compounded by poor healing of wounds and neuropathy 
(particularly of the feet), can lead to gangrene which more often than not requires 
amputation. In fact, diabetes is the leading cause of non-traumatic amputation in 
adults in the developed world. 
 
1.1.2 Aetiology and Genetics of Diabetes Mellitus 
The exact aetiology of diabetes mellitus is incompletely understood but it 
is widely accepted that it is multifactorial and that both genetic and environmental 
factors play a role. 
 
Type 1 Diabetes Mellitus 
 Although type 1 diabetes is not a genetically predestined disease, an 
increased susceptibility can be inherited. This is evident by the fact that identical 
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(monozygotic) twins have a higher concordance rate (13%-47%) for type 1 
diabetes compared to non-identical (dizygotic) twins (0%-8%) [3-5]. Further 
evidence of genetic involvement is that 95% of type 1 diabetics carry HLA-DR3, 
HLA-DR4 or both [6]. The most important genes contributing to disease 
susceptibility are located in the HLA class II locus on the short arm of 
chromosome 6 [7]. Nevertheless, only a relatively small proportion (<10%) of 
genetically susceptible individuals progress to clinical disease, this implies that 
additional genetic and/or environmental factors are involved in the pathogenesis 
of type 1 diabetes [8].  
 There is a major ethnic and geographical difference in the incidence and 
prevalence of type 1 diabetes [9]. The highest reported cases are seen in the 
Nordic countries while the lowest incidence is seen in Asia. Low rates are also 
reported in Africa and Latin America. These differences are possibly due to 
variations in environmental factors. 
 Viruses have long been implicated in the pathogenesis of type 1 diabetes. 
In the Finnish Diabetes Prediction and Prevention Study, enterovirus infection 
was found to be a risk factor in the development of beta cell autoimmunity [10]. 
Increased risk of type 1 diabetes was also reported in children with recent 
infection [11]. Furthermore, there appears to be a seasonal variation in the 
incidence of type 1 diabetes with higher rates occurring in autumn and winter 
compared to the warmer months [8]. Consumption of cow’s milk protein in early 
life has also been found to increase a child’s susceptibility to type 1 diabetes [11, 
12]. 
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Type 2 Diabetes Mellitus 
 The majority of diabetic patients have type 2 diabetes and its prevalence 
is on the increase. Many genes have been shown to be associated with type 2 
diabetes. These include Gc genotype gene located on chromosome 4, HLA gene 
on chromosome 6, lipoprotein antigen gene on chromosome 6, insulin gene 
polymorphism on chromosome 11, apo-lipoprotein genes on chromosomes 2 and 
11, glucose transporter genes on chromosomes 1 and 12, haptoglobin gene on 
chromosome 16, and insulin receptor gene on chromosome 19 [13]. 
 Genetic susceptibility plays a crucial role in the aetiology and 
manifestation of the disease, with the concordance rate in monozygotic twins to 
be between 58% to 100% [14, 15]. Warram showed that in the offspring of type 2 
diabetic parents, reduced glucose clearance and compensatory 
hyperinsulinaemia preceded the development of type 2 diabetes by 10-20 years 
[16]. However, a study in Denmark suggests that even though genetic factors 
may be important in the development of abnormal glucose tolerance, non-genetic 
factors possibly have a predominant role in controlling whether a genetically 






1.1.3 Burden of the Disease 
The World Health Organization estimates that in 2006 more than 180 
million people worldwide suffer from diabetes and that this number will double by 
the year 2030 [18]. Although diabetes mellitus is more common in the more 
developed countries, the greatest increase in prevalence is expected to occur in 
Asia and Africa. 
 In the United States of America (USA), there were 20.8 million children 
and adults (7% of the population) with diabetes in 2005 [19]. A study conducted 
by the Levin Group, Inc. for the American Diabetes Association estimated the 
cost of diabetes in the United States in 2002 was $132 billion [20]. In Singapore, 
the prevalence of diabetes in the population is 8.2% according to the 2004 
National Health Survey [21].   
 The acute complications of diabetes: diabetic ketoacidosis, nonketotic 
hyperosmolar coma and hypoglycaemia, have become less common with the 
introduction of insulin and its various formulations. As diabetics have begun to 
live longer, however, the chronic complications of diabetes, in the form of heart 
disease (angina and heart attacks), stroke, renal failure, neuropathy, peripheral 
vascular disease, amputations and blindness, have taken over as the principal 




1.2 Current Treatment for Diabetes Mellitus 
 The aim of diabetes treatment is to maintain blood glucose levels as close 
to the normal range as possible under conditions of daily living. Diabetics have to 
avoid acute problems of hyperglycaemia or hypoglycaemia as well as minimize 
the chronic diabetic complications as mentioned above.  
Patients with type 1 diabetes require daily direct administration of insulin 
as their bodies do not produce enough (or even any) endogenous insulin. 
Traditionally, insulin could only be administered by injections, but recently an 
inhaled form has been developed. Exubera, an inhaled product, was approved by 
the Food and Drug Administration (FDA) and was made available in USA in 
2006.  
Insulin therapy is supplemented with other measures including nutrition 
therapy, planned physical activity and frequent blood glucose testing. The 
Diabetes Control and Complications Trial (DCCT) showed that good control of 
blood glucose levels with intensive insulin treatment delays the onset and slows 
the progression of complications of type 1 diabetes mellitus [22, 23].  
For type 2 diabetics, treatment consists mainly of a combination of 
nutrition therapy, exercise, attainment of ideal body mass index and, in some 
cases, oral hypoglycaemic agents. Obesity is very common in type 2 diabetics 
and contributes greatly to insulin resistance. Exercise and weight loss improves 
tissue sensitivity to insulin and allows its proper use by target tissues. In fact, it 
has been shown that in patients with impaired glucose tolerance, changes in 
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lifestyle can prevent the development of type 2 diabetes [24]. However, some 
type 2 diabetics eventually fail to respond to these treatment methods and must 
proceed to insulin therapy for good glycemic control.   
However, despite the advances in insulin preparation and delivery, 
exogenous insulin therapy is still a poor substitute for the rapid and finely 
regulated process of endogenous insulin secretion in response to changes in 
blood glucose levels. Insulin injections do not replicate the physiological 
dynamics of meal-related insulin secretion. Most diabetic patients resist initiation 
of exogenous insulin therapy, are likely to be poorly compliant in self-monitoring 
of blood glucose levels and fail to adjust their insulin doses resulting in 
suboptimal control.  
Furthermore, iatrogenic hypoglycaemia, whether medication-induced or 
insulin-induced, remains a limiting factor in achieving perfect glycaemic control 
[25] and leads to significant morbidity and even mortality. For example, children 
on conventional insulin therapy suffer hypoglycaemic comas and convulsions at 
estimated rates of 20 events per 100 patient years [26]. Glycaemic control 
among diabetic patients remains unsatisfactory and may have deteriorated in 
recent years [27]. If these patients could reacquire a source of endogenous 
regulated insulin secretion by pancreas or islet transplantation, cell-based 
therapy or gene-based therapy, it would reduce dependence on insulin injections 
(in type 1 diabetics) and/or supplement failing islet function (in type 2 diabetics). 
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1.2.1 Allogeneic Islet Transplantation 
Clinical success with allogeneic islet transplants was widely hailed in the 
beginning, however, several limitations have prevented its widespread adoption. 
Firstly, there is the problem of shortage of donors because each successful 
transplant requires at least two, and often more, donors [28]. And although most 
recipients treated successfully can be taken off insulin, the normal insulin-
glucose dynamics is not restored in them [29]. Furthermore, an international, 
multicenter trial employing the ‘Edmonton protocol’ for islet transplantation 
showed that the insulin independence achieved after transplantation is usually 
not sustainable [30]. 
Patients undergoing allogeneic islet transplants also have to receive long-
term immunosuppression therapy with all its potential side effects. 
Immunosuppressive regimens that prevent allorejection of kidney, heart, or liver 
seem to fail with human islets. The main component of these regimens is 
glucocorticoids which have been shown to produce insulin resistance de novo 
[31] and also decrease islet endocrine function [32, 33]. Other agents, such as 
cyclosporine and tacrolimus, have been associated with a deterioration in renal 
function which alters glucose metabolism and insulin kinetics [34, 35]. Most 
significantly, long-term immunosuppression has been associated with the 
development of malignancy [34, 35]. 
Recurrence of disease in type 1 diabetics is another obstacle. Several 
studies have suggested that this was the cause of the loss of function of 
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transplanted islets despite immunosuppression and HLA matching. This was 
demonstrated in pancreas transplantations between monozygotic twins [36]. The 
reappearance of GAD65 autoantibodies, a major serological marker for type 1 
diabetes, has been associated with failed islet transplants [37]. 
 
1.3  Experimental Approaches to Treatment of Diabetes Mellitus 
 
1.3.1  Cell-Based Therapy for Diabetes Mellitus 
Cell-based therapy includes all methods that involve the creation or 
expansion of insulin-producing cells in vivo or in vitro followed by their 
transplantation in vivo. The cells involved could be stem cells (either embryonic 
stem cells or adult progenitor cells) that have been induced to differentiate into 
beta cells in vitro, or native beta cells that undergo in vivo stimulation of 
regeneration or ex vivo induction of expansion. Alternatively, they could be non-
beta cells manipulated to produce insulin by ex vivo gene therapy (as discussed 
under the gene therapy section 1.3.2). 
 
1.3.1.1 Stem Cells 
Large numbers of replacement beta cells are required to produce a 
significant therapeutic impact in diabetes treatment. Current transplantation 
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protocols use up to 1x106 primary human islets per recipient, this is equivalent to 
approximately 2-4x109 beta cells. Mature beta cells have a very low proliferative 
capacity [38], thus the ability of stem cells to be expanded considerably in vitro 
before differentiation into the mature beta cell phenotype make them attractive 
candidates for producing replacement beta cells for use in transplantation. 
Islet cell clusters have a biphasic response to an increase in glucose 
levels: a rapid release of high concentrations of insulin and a slower release of 
lower concentrations of insulin. In contrast, isolated beta cells do not release 
insulin in this manner. Instead it is an all-or-nothing response with no fine 
regulation for intermediate concentrations of glucose [39, 40]. Intraislet signalling 
may be the reason for this. Thus, it is preferable to culture stem cells to produce 
all the cells of the islet cluster. 
Embryonic stem cells 
Embryonic stem cells are derived from the inner cell mass of a blastocyst. 
They are able to differentiate into almost every adult cell type (pluripotent) and 
can also self renew extensively. Various strategies have been reported for 
deriving insulin-expressing cells from embryonic stem cells i.e. by permitting 
spontaneous differentiation [41, 42], in vitro culture under selective conditions 
[43], via enrichment of presumptive neuroendocrine progenitor (nestin-positive) 
cells [44], by forced expression of beta cell transcription factors [45, 46] or by 
using a beta cell active promoter-reporter construct to signal differentiation into 
an insulin-producing cellular phenotype [47, 48].  
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However, as is common with studies using stem cells, the cellular identity 
of these insulin-expressing cells is uncertain and there remains the possibility 
that these are not fully mature beta cells but a phenotypically similar population 
of cells. Furthermore, in the genetically manipulated stem cells, there is the risk 
of tumorigenicity [49, 50]. 
Adult progenitor cells 
A variety of adult tissues harbour progenitor or stem cells. The pancreas is 
an obvious source of stem cells that can be induced to adopt some elements of a 
beta cell phenotype. Murine and human pancreatic duct cells have been grown in 
culture to yield cells organised in islet-like aggregates that release insulin in 
response to glucose stimulation [51, 52]. Others have used islet precursor cells, 
including nestin-positive ones, to generate beta-like cells that demonstrate 
glucose-dependent insulin release [53-55]. More recently, pancreatic exocrine 
(acinar) cells have also been transdifferentiated to insulin-producing cells in vitro 
[56, 57]. 
As the liver has a common embryonic origin with the pancreas, it is 
believed that it harbours cells that are capable of transdifferentiating to 
pancreatic cell lineages. Most success has been seen with transduction of Pdx-1 
into liver cells with or without culture in high-glucose medium. These cells were 
reprogrammed to a beta-cell phenotype with insulin secretion and correction of 
hyperglycaemia [58-62]. NeuroD, an islet transcription factor downstream of Pdx-
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1, in combination with betacellulin was also able to induce insulin-producing cells 
in the liver in diabetic mice [63]. 
 Stem cells derived from bone marrow are also considered a prospective 
source for pancreatic beta cells. They have been successfully differentiated in 
vitro and in vivo into insulin-expressing cells [64-66]. Other tissues that have 
been investigated for progenitor cells that can transdifferentiate to insulin-
producing cells or cells expressing beta cell markers include umbilical cord blood 
[67, 68], spleen [69], adipose tissue [70], salivary glands [71], blood [72], 
amniotic epithelium [73], and central nervous system [74, 75] 
 
1.3.1.2 Regeneration of Primary  Pancreatic Beta Cells 
Pancreatic beta cells do proliferate under normal physiological conditions 
but at a low rate [76]. In vivo stimulation of regeneration with molecular therapies 
or ex vivo induction of expansion may be used to produce large numbers of 
functional beta cells. Glucagon-like peptide-1 (GLP-1) and its analog exendin-4 
can stimulate beta cell insulin secretion, inhibit apoptosis, and increase cell mass 
in rodents [77-80]. Recent clinical trials of exendin-4 on type 2 diabetic patients 
showed improvement of glycaemic control associated with no weight gain [81, 
82].  
Other factors that have been shown to increase beta cell proliferation and 
expand beta cell mass are Reg protein [83], islet neogenesis gene-associated 
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protein [84], hepatocyte growth factor [85], insulin-like growth factor [86], 
betacellulin [87], and the combination of EGF and gastrin [88]. 
 
1.3.1.3 Problems with Current Cell-based Therapy Approaches 
Cell replacement therapy for diabetes with the use of embryonic stem 
cells, adult progenitor cells or regenerating beta cells is promising but there are 
significant challenges ahead. Derivations of insulin-producing cells via these 
methods have been characterized by low efficiency and production of highly 
heterogeneous cell populations. 
In the case of embryonic stem cells, there is particular concern about the 
risk of tumorigenicity. It has been shown that transplanted embryonic stem cells 
can form teratomas in mice [49]. Karyotypic abnormalities have also been 
observed in some embryonic stem cell lines after prolonged culture [89, 90].  
The immunocompatibility of cells derived from embryonic stem cells is 
another issue, especially so in the case of type 1 diabetes which is an 
autoimmune condition. However, studies have shown that embryonic stem cells 
have low immunogenicity [91, 92]. Further reduction of host reactivity can be 
achieved through immunosuppression but it is not without serious side effects. 
The transplanted cells can also be engineered to cause minimal stimulation of 
immune response, either by encapsulation in biocompatible matrices, by 
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modification to display particular human leukocyte antigen (HLA) profiles, or by 
eliminating proteins of the major histocompatibility complex (MHC) [93]. 
As for adult progenitor cells, they are more often than not isolated in small 
numbers as part of heterogeneous populations. Standard isolation and 
purification protocols for these cells are also lacking. Furthermore, most adult 
progenitor cells have limited proliferation potential and the factors that promote 
their proliferation are not fully known. The presence of mitogenic factors in 
current culture protocols for progenitor cells may contribute to the appearance of 
genetically abnormal strains over time. 
Thirdly, many progenitor cells have limited plasticity which makes their 
differentiation to distant cell types uncertain. In fact, alternative explanations to 
transdifferentiation have been put forward [94]. Lastly, the use of adult progenitor 
cells as transplants of autologous beta cells or islets may result in recurrent 
autoimmune rejection in type 1 diabetes. Their immunogenic profile will have to 
be altered to reduce this prospect. 
In the regeneration of primary pancreatic beta cells, the main hurdle 
seems to the scaling up of these processes to generate clinically relevant 
quantities of cells for therapies. Large surface areas will need to be available to 
expand the cells. 
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1.3.2 Gene-based Therapy for Diabetes Mellitus 
Gene therapy includes any approach that involves the introduction of an 
exogenous gene into any cell type inducing it to produce insulin. There are two 
gene delivery methods: in vivo, whereby the gene therapy vector is administered 
directly to the subject; and ex vivo, whereby cells are transduced or transfected 
with a therapeutic gene in vitro and then transplanted into the subject. 
In vivo gene therapy is the preferred method of delivery because of its 
simplicity and convenience. However, the development of safe and effective 
vectors for in vivo therapy is demanding as toxicity related to the vector is often 
the limiting factor. Other major problems of the in vivo method are low efficiency 
of gene transfer, difficulty in targeting gene transfer to the desired tissue(s) and 
risk of inadvertent germ line modification.  
The main difficulty with ex vivo therapy is the mechanics of transplanting 
the genetically modified cells back in the host. Ex vivo therapy is also only 
realistic with primary cells which in themselves are hard to expand in culture, 






1.3.2.1 In vivo Gene Therapy 
Non-insulin genes 
 Non-insulin transgenes lower blood glucose by inhibiting hepatic 
gluconeogenesis and also enhancing glucose utilization by the liver or skeletal 
muscle. Several studies have employed glucokinase (Gck) gene transfer to 
correct diabetes in rodents [95-98]. Others have used gene transfer of the Gck 
regulatory protein which produces a similar effect [99].  
 Overexpression of a mutant form of 6-phosphofructo-2-kinase/fructose-
2,6-bisphosphatase has been shown to increase fructose-2,6-bisphosphate 
levels which in turn downregulates glucose-6-phosphatase and upregulates Gck 
gene expression which stimulates glucose disposal and inhibits hepatic glucose 
production in a mouse model of type 2 diabetes [100]. Lastly, adenovirus-
mediated transfer of ‘protein targeting to glycogen’ (PTG) stimulates glycogen 
synthesis in the liver and lowers blood glucose in rats [101]. 
Glucose-responsive insulin genes and their variants 
 In this approach to gene therapy, the insulin genes, or their precursors, 
are modified either to make the proinsulin expressed in non-neuroendocrine cells 
susceptible to processing into mature insulin or to avoid the need for processing 
altogether. In several studies, investigators have modified the coding sequence 
for proinsulin to specify new cleavage sites that are recognized by furin, a/an 
ubiquitous endoprotease [102-104]. These genes are then introduced into liver 
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cells, which is just one of many tissues that express furin. Alternatively, the 
insulin gene can be modified to encode single-chain insulin which has 20-40% of 
the activity of normal mature insulin [105]. 
 The second modification involves making the expression of the insulin 
transgene responsive to changes in blood glucose concentration. Several 
glucose-responsive promoters have been used, such as promoters from the 
phosphoenolcarboxykinase gene [106], elements from the L-pyruvate kinase 
gene [107], the glucose-6-phosphatase gene [108], and those based on the S14 
gene [109]. However, in these promoters, there is a lag in the insulin secretory 
response by 1-2 hours compared to the instantaneous burst of insulin produced 
by normal beta cells. Another approach is to control secretion at the level of the 
endoplasmic reticulum by drug-induced protein disaggregation [110]. 
 
1.3.2.2 Ex vivo Gene Therapy 
Ex vivo somatic cell gene therapy begins with selection of an appropriate 
somatic cell type, whether autologous or not, which can act as surrogate beta 
cells. The cells are transduced or transfected in vitro with genes that confer the 
ability to synthesise, process and release insulin in response to certain stimuli. 
These modified and selected cells can then be expanded in vitro before 
reimplantation or cryopreservation. In vitro studies can be performed before 
reimplantation to assess their functional properties. Surgical intervention may be 
required depending on the site of implantation. 
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Both Ltk and NIH3T3 fibroblasts have been employed in studies of this 
type [111-113]. Modification of these cells with a preproinsulin transgene and 
implantation into diabetic mice led to correction of hyperglycaemia. Pituitary 
AtT20 cells have an endogenous capacity as neuroendocrine cells to process 
proinsulin to mature insulin. Transfection of these cells with human preproinsulin 
DNA and subsequent implantation into diabetic mice reduced the severity of 
hyperglycaemia [114].  
Further advances in this area involved the use of promoters to regulate 
insulin transgene expression. Tuch et al utilised a human liver cell line, HUH7, 
and transfected it with human insulin cDNA under the control of the 
cytomegalovirus promoter [115]. The transfected cells were surprisingly able to 
synthesize and secrete insulin in a regulated manner and, when transplanted into 
diabetic mice, able to normalize blood glucose levels. Another study utilised an 
established line of intestinal K cells to express transgenic human insulin from the 
regulatory region of the glucose-dependent insulinotropic polypeptide (GIP) gene 
and this protected mice from developing diabetes after destruction of the native 






1.4 Our Approach 
Our approach was to obtain primary adult hepatocytes from diabetic cynomolgus 
macaques (Macaca fascicularis) and modify them ex vivo with a plasmid 
construct that contained the proinsulin cDNA sequence under the control of a 
bifunctional promoter. The engineered autologous hepatocytes were then 
implanted into the same diabetic cynomolgus macaques in order to correct their 
hyperglycaemia. 
1.4.1 Plasmid Construct 
The gene vector used in this study was an expression plasmid of human 
proinsulin cDNA that encoded the HisB10Asp variant. This variant has a 
substitution of aspartic acid for histidine-10 of the B chain of insulin. It has higher 
biological potency than native insulin and is secreted more rapidly through the 
constitutive pathway [117, 118]. 
Most non-endocrine cells are not able to process proinsulin to insulin 
because they do not express the required three enzymes (two endopeptidases, 
PC1/3 and PC2, and an exopeptidase carboxypeptidase-H) [119, 120]. Proinsulin 
has less than 10% of the activity of insulin and is not suitable for insulin 
replacement. One way to achieve proinsulin processing is to utilize the ubiquitous 
endoprotease furin. The human proinsulin CDNA sequence in our plasmid 
construct was modified to be furin-cleavable by introducing tetrabasic motifs into 
the amino acid sequence of wild-type proinsulin at the B chain / C-peptide and C-
peptide / A chain junctions [102, 118, 121]. 
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The human proinsulin cDNA was placed under the control of a bifunctional 
promoter comprising the human metallothionein IIA promoter linked to a single 
copy of the carbohydrate response element (ChoRE) from the L-type pyruvate 
kinase (LPK) gene [122]. Adequate inter-prandial insulin expression would occur 
as the metallothionein IIA promoter has basal activity in hepatocytes, while post-
prandial stimulation of insulin secretion would occur via glucose activation of 













Figure 1. Plasmid construct used in this study 
Human proinsulin cDNA, modified to be furin-cleavable and to encode the 
HisB10Asp variant, was driven by a bifunctional promoter comprising the human 
metallothionein IIA promoter linked to a single copy of the carbohydrate response 
element (ChoRE). 
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1.4.2 Autologous Primary Hepatocytes 
Hepatocytes are suitable candidates for surrogate beta cell function as 
they have non limiting rates of glucose transport into the cell and glucose 
phosphorylation predominantly by the high Km enzyme glucokinase. They also 
normally regulate the expression of certain genes (e.g. L-type pyruvate kinase, 
acetyl CoA carboxylase) in response to changes in ambient glucose levels. One 
way this occurs is probably via the transcription factor ChREBP [123]. 
Hepatocytes are abundant and this overcomes the primary problem of cell 
shortage as seen in islet transplantation. Furthermore, the liver has the 
remarkable ability to massively regenerate following various types of injuries until 
it regains its original mass. In rats, hepatocytes start to proliferate within a few 
hours after partial hepatectomy and restore the initial total hepatocyte mass 
within 4 days [124]. Indeed, they represent a renewable source for beta cell 
surrogates.  
In using hepatocytes as autologous transplants, the need for lifelong 
immunosuppression, and its unwanted side effects, is avoided. Adult primary 
hepatocytes are not a cell line and, being non-mitotic, are a safer option with no 
malignancy risk and low probability of hyperinsulinaemic hypoglycaemia. The risk 
of recurrence of disease due to autoimmune destruction of transplanted cells, as 
seen in islet transplantation for type 1 diabetes, is also not an issue [125]. 
Hepatocyte transplantation has been conducted in animal models of 
metabolic liver disease with promising results. Studies have shown that 
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transplantation of hepatocytes reduces bilirubin levels in Gunn rats, increases 
serum albumin in Nagase analbuminaemic rats, and corrects the metabolic 
abnormalities in murine models of histidinemia, rabbit models of 
hypercholesterolaemia due to LDL receptor deficiency, and a number of other 
liver-based metabolic disorders [126-131]. 
 In humans, experimental hepatocyte transplantation, whether autologous 
or allogeneic, has been carried out in an attempt to treat familial 
hypercholesterolaemia, ornithine transcarbamylase (OTC) deficiency, glycogen 
storage disease type Ia, infantile Refsum disease and Crigler-Najjar syndrome 
type 1 [132-136]. However, the metabolic correction observed in all these cases 
has been modest and unsustained.    
 
1.4.3 Transplantation Site 
The presence of a physiological matrix and the availability of a portal 
blood supply make the liver the optimum site for hepatocyte transplantation. Its 
strategic location in the portal circulation allows for rapid sensing of nutrient 
signals and the release of higher concentrations of insulin into the portal 
circulation than the peripheral circulation, in contrast to exogenous insulin 
therapy.  
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The subcutaneous tissues and peritoneal surface are inefficient in 
supporting long-term attachment and survival of liver cells, while the renal 
subcapsular space can accommodate only a small number of liver cells [137]. 
Hepatocyte transplantation into the liver has been more commonly 
performed by the portal vein infusion technique.  However, we chose the direct 
intraparenchymal implantation technique for our study as the portal vein infusion 
method has significant disadvantages. More than 70% of portal vein-infused 
hepatocytes are trapped within the liver vascular bed and destroyed within 24 
hours by blood macrophages [138]. Moreover, up to 50% of portally-infused 
hepatocytes are distributed to extrahepatic organs e.g. lungs, and could cause 
clinical thromboembolism [139]. In contrast, hepatocytes transplanted directly 
into the liver parenchyma did not distribute to other organs and integrated 
normally into liver lobules [140].   
 
1.4.4 Primate Model of Diabetes 
We have previously shown that transfected primary hepatocytes can 
provide a quasi-physiological source of insulin that restores euglycemia in 
diabetic mice [141]. However, outcomes in rodent transplant models do not 
reliably predict those in larger mammals such as humans and nonhuman 
primates [142, 143]. Indeed, the many ways that the NOD mouse can be cured 
have been shown to be poorly applicable to human type 1 diabetes [144]. 
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Nonhuman primates (NHP) have long been regarded as the ‘gold 
standard’ for preclinical studies in the field of transplantation as they have 
evolutionary proximity to humans with whom they exhibit an overall >95% 
homology at the genome level [145]. 
The spontaneous development of type 1 diabetes mellitus has been 
reported in nonhuman primates [146, 147]. Diabetes has been induced, for 
controlled experiments, in nonhuman primates with the use of streptozotocin 
(STZ), alloxan, or total pancreatectomy [146]. STZ has been used the most 
extensively because it is the least invasive and perhaps the most efficient way to 
induce diabetes. On the other hand, total pancreatectomy is associated with high 
surgical morbidity and mortality, and the exocrine pancreatic deficiency that is 
induced with this method results in reduced absorption and inconsistent drug 
levels [148].  
In nonhuman primates, the administration of a low dose of streptozotocin 
(30–55 mg/kg) is unreliable because it inconsistently induces C peptide–negative 
diabetes [149-152]. The use of higher streptozotocin doses (100–150 mg/kg) has 
been effective in inducing C peptide–negative diabetes but is associated with 





CHAPTER 2: MATERIALS AND METHODS 
 
2.1 Plasmid Construct 
Human proinsulin cDNA sequence was modified to encode the HisB10Asp 
variant and to introduce furin cleavage sites at the B chain / C-peptide and C-
peptide / A chain junctions by PCR-based mutagenesis. The human proinsulin 
expression was driven by a bifunctional promoter comprised of a 3 kb fragment 
of the human metallothionein IIA promoter linked to a single copy of the 
carbohydrate response element (ChoRE). The resulting modified construct, 
p3MTChins, was used in all experiments. 
 
2.2 Hepatocyte Isolation 
After partial resection of a liver lobe (see below in section 2.6.4), 
hepatocyte isolation was performed  as described by Bumgardner et al [158] with 
the following modifications. The resected liver was sequentially perfused in situ 
with 2.5mM EGTA in calcium-free Dulbecco’s phosphate buffer (prepared with 
deionized water) and with 0.3% collagenase IV-S (Sigma-Aldrich) dissolved in 
the same buffer solution (prepared with distilled water) via a catheter placed in 
the main portal vein branch at the excised liver surface. The perfusion times were 
8-10 and 15-20 minutes respectively, at a flow rate of 8-10 ml/min.  
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 The perfused liver was then minced and scraped to release the cells. The 
cells were filtered through a cotton bag into fresh, ice-cold DMEM-high glucose 
supplemented with 12% foetal calf serum (FCS). A cellular fraction enriched in 
hepatocytes was obtained as a pellet after centrifugation (150g, 15 min at 4oC) 
on a discontinuous Percoll (GE Healthcare) gradient (15-30-45-60%). The 
number of viable cells was determined by trypan blue exclusion. 
 
2.3 Gene Transfer 
Primary porcine hepatocytes were electroporated with a sterile solution, 
developed in our own laboratory, having the following composition: 19.8 mM 
KH2PO4 / 80.2 mM K2HPO4 / 2 mM NaCl, pH 7.6. Freshly prepared 2 mM ATP 
and 5 mM reduced L-glutathione were added to the solution just before use. 
Electroporation was performed in the Amaxa NucleofectorTM electroporation 
device (Amaxa GmbH, Germany). Various program settings were tested. Eight 
µg of endotoxin-free plasmid DNA (p3MTChins or pEGFP) was added to 4 x 106 
viable hepatocytes in 0.2 ml electroporation solution before electrical pulsing. 
Cells were transferred to DMEM supplemented with 15% FCS (for in vitro 
characterization) or DMEM without phenol red and FCS (for transplantation in 





2.4 In vitro Studies 
 
2.4.1 Induction of Insulin Expression 
After initial plating of 2 x 106 hepatocytes on collagen I-coated 35 mm 
dishes, non-adherent and dead cells were removed by medium change 3-5 hours 
later. The cells were cultured in DMEM-25 mM glucose (supplemented with 10% 
FCS, penicillin 10,000 units/ml and streptomycin 10 mg/ml) in 5% CO2 at 37°C for 
at least 16 hours.  
For static induction, electroporated hepatocytes were cultured in DMEM 
with increasing concentrations of glucose alone (2.5, 10, 15 and 25 mM) or zinc 
(5, 10, 20, and 60 µM) combined with 25 mM glucose. Glucose concentrations of 
15 and 25 mM represent the conditions found in severe diabetes mellitus. 
Conditioned media (24 hours) of triplicate plates were assayed for human insulin.  
For a kinetic study of glucose-responsive insulin production, the culture 
medium of overnight plated hepatocytes was changed from DMEM-25 mM 
glucose to DMEM-2.5 mM glucose 3 hours before commencing induction. 
Replicate plates were then exposed to DMEM-25 mM glucose for 5, 10, and 60 
minutes.  The baseline time point of 20 minutes before cells were exposed to 25 
mM glucose was taken as the unstimulated value. A parallel series of plates, 
after exposure to DMEM-25 mM glucose for 60 minutes, was returned to DMEM-
2.5 mM glucose for a further 20 and 60 minutes during the de-induction phase.  
At each time point during both induction and de-induction phases, each plate (3 
plates per time point) was processed for human insulin assay in the conditioned 
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medium and total cellular RNA isolation (RNeasy Fibrous Tissue kit, Qiagen, 
Germany) according to the manufacturer’s protocol.  
 
2.4.2 Transcriptional Induction of Transgene (RT-PCR) 
cDNA was generated from the RNA isolated at various time points using 
SuperScript II Rnase H reverse transcriptase (Invitrogen, USA) and the supplier’s 
recommended reaction protocol. Each 20 µl reaction contained 10 µl RNA. In all, 
1 µl from the reverse transcriptase reaction was used as template for semi-
quantitative PCR comprising 0.8 µM each of forward and reverse primers, 1.6 
mM magnesium chloride, 6.25 µl Quantitect SYBR Green PCR master mix 
(Qiagen, Germany) and sterile water to a final volume of 12.5 µl. 
Primer sequences for human insulin mRNA were 5' TTT GTG AAC CAA 
CAC CTG TGC 3' (forward) and 5' GGT TCA AGG GCT TTA TTC CAT CT 3' 
(reverse). Intron-spanning primer sequences for primate hypoxanthine 
phosphoribosyltransferase I (HPRT I) mRNA were 5' GGA TTA CAT CAA AGC 
ACT GAA TAG 3' (forward) and 5' GGC TTA TAT CCA ACA CTT CGT G 3' 
(reverse). Thermal cycling conditions (Opticon, MJ Research, USA) were 95oC 
for 15 minutes, followed by 49 cycles of 95oC x 30 seconds / 68oC x 30 seconds / 
72oC x 20 seconds / 75oC x 1 second. Melting curves (65-95oC) confirmed 
amplification of a single product in all reactions. Data were analyzed using the 
Opticon Monitor Analysis software, version 1.07 (MJ Research, USA). 
Differences in input RNA amounts were normalized using Ct values 
obtained in parallel reactions for primate hypoxanthine 
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phosphoribosyltransferase (HPRT1) mRNA and spurious amplifications were 
corrected by minus RT controls. Corrected data are expressed as fold change of 
gene-specific mRNAs over basal mRNA. Human and primate insulins, HPRT1, 
and the respective minus RT controls were measured in triplicate samples. Each 
sample was assayed in quadruplicate RT-PCR reactions.  
 
2.5 Hormone Radioimmunoassay 
Human insulin concentrations were determined using radioimmunoassay 
and the supplier’s protocols (Linco Research, USA) 
 
2.6 Animal (in vivo) Studies 
Cynomolgus macaques (Macaca fascicularis) supplied by the SGH Animal 
Husbandry and Hospital, Sembawang, Singapore were used in our study. All 
animal handling procedures and animal husbandry were conducted in an 
AAALAC-accredited facility. The experimental protocol was approved by the 
Institutional Animal Care and Use Committee of the Singapore General Hospital. 
We used male and female macaques weighing 2.5 – 5.0 kg. They were fed twice 
daily (10 pellets of chow at 0900 hours and 8 pellets of chow and 1 fruit at 1530 
hours) and allowed water ad libitum. 
 
2.6.1 Sedation and Anaesthesia 
Intramuscular Ketamine (25 mg/kg) injections were used to sedate the 
animals for blood withdrawals and streptozotocin administration. For longer 
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procedures (intravenous glucose tolerance test) and surgical procedures, 
anaesthesia was maintained with isoflurane (2-3%) inhalation. 
 
2.6.2 Blood Glucose Monitoring and Venepucture 
Capillary blood glucose was obtained by lancing either fingers, toes or the 
abdominal wall and measured with a glucometer (Ascensia ELITE®, Bayer 
Healthcare, Germany) in awake animals. Blood was drawn periodically, via 
venepuncture of the femoral vein under sedation, for measurements of human 
insulin, serum electrolytes, lipids (triglycerides and total cholesterol), biochemical 
tests of liver function (total protein, albumin, total bilirubin, alkaline phosphatase, 
serum alanine transaminase (ALT) and γ-glutamyl transferase (γGT) activities), 
renal function (urea and creatinine) and full blood counts (total and differential 
leucocyte counts, haemoglobin concentration, total red blood cell count and 
erythrocyte indices, and platelet count).  
 
2.6.3 Intravenous Glucose Tolerance Test (IVGTT) 
We performed IVGTT on animals at three time points during the study – 
prediabetic (before streptozotocin injection), diabetic (after streptozotocin 
injection), and post-hepatocyte transplant. Animals were fasted overnight and 
anaesthetized. Two intravenous catheters were inserted: one into the saphenous 
vein for saline and glucose administration and one into the contralateral femoral 
vein for blood sampling.  
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To establish the baseline, a bolus injection of saline (equal to the volume 
of glucose solution) was administered over 3 minutes and blood was drawn 5 
and 10 minutes later for blood glucose levels and plasma human insulin assays. 
IVGTT was initiated by a bolus injection of glucose (0.5 g/kg as a 25% w/v 
solution) over 3 minutes followed by a second saline (2 ml) injection to flush the 
line. One ml of blood was drawn 1, 3, 5, 10, 20, 30, 45 and 60 minutes after the 
intravenous glucose bolus for the same assays. In order to avoid possible 
artefacts caused by hypovolemia, one ml heparinized saline was injected after 
each blood sampling.  
Area under the curves (AUC) of glucose and insulin were calculated using 
the Trapezoidal Rule. The K-value or elimination rate constant of the curves was 
calculated by the formula: 0.693/half life. 
 
2.6.4 Induction of Diabetes 
After hydration with subcutaneous normal saline (1 ml/kg/hr) for 16 hours 
the day before, intravenous streptozotocin (65-120 mg/kg, Zanosar, Pfizer) was 
administered as a bolus injection over 5 minutes via a femoral vein catheter 
under general anaesthesia. Hydration was continued for 16 hours after the 
streptozotocin injection with subcutaneous normal saline (1 ml/kg/hr). 
Exogenous insulin injections (Lantus, Sanofi Aventis; Actrapid, Novo 




2.6.5 Liver Resection and Hepatocyte Transplantation 
Under general anaesthesia, the abdominal cavity was entered through a 
left subcostal incision and the left liver lobe was mobilized. A non-crushing clamp 
was applied across the lobe and 30-50% of the left lobe was resected en masse 
(less than 13% of the total liver volume). The main portal vein branch was 
immediately cannulated and hepatocyte isolation and electroporation was 
performed as described above. Haemostasis of the remnant liver was achieved 
with 5/0 Prolene (Ethicon, USA) sutures and diathermy. Surgicel (Johnson & 
Johnson) was applied to the resected surface. 
Transfected hepatocytes in suspension were injected under direct vision 
into four sites (2 sites each in the right central and left central lobes) using a 23G 
needle (1-1.5 ml/site) at a depth of 5 to 10mm. The number of hepatocytes 
transplanted into each animal is reflected in Table 2 (page 50). Transplantation 
sites were marked with a 5/0 Prolene suture. The abdominal incision was closed 
using 3/0 Ethilon and the skin with 5/0 Vicryl (both Ethicon, USA). 
Post-operatively, antibiotic cover with enrofloxacin (5 mg/kg IM) or co-
amoxiclav (11 mg/kg IM) was given for 5 days. Buprenorphine (0.01 mg/kg IM) 
was also given for 5 days as analgesia. 
 
2.7 Statistical Analysis 
Data were expressed as mean ± s.e.m. Statistical significance was 
determined by Student’s unpaired t test for independent samples. The difference 
between two groups was considered significant when p < 0.05. 
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CHAPTER 3: RESULTS 
 
3.1 Electroporation of Primary Hepatocytes 
Transfection of primary hepatocytes was achieved using the Amaxa 
Nucleofector TM system apparatus and a sterile solution developed in our 
laboratory. We initially used various program settings on the Amaxa apparatus to 
transfect the cells with a reporter plasmid expressing green fluorescent protein 
(pEGFP) to assess transfection efficiency and cell viability (Figure 2). 
Program A23 was associated with the highest viability but low transfection 
efficiency with the hepatocytes producing low levels of human insulin. On the 
other hand, program T20 had the highest efficiency but with moderate 70% 
viability. We settled on program H22 for all future electroporation in the study as 










































Figure 2. Electroporation of primary primate hepatocytes 
 
Electroporation of isolated primary primate hepatocytes was performed using the  
Amaxa Nucleofector system. Various program settings were tested with a 
reporter plasmid expressing green fluorescent protein (pEGFP) to assess 
transfection efficiency and cell viability. Program H22 provided a combination of 
acceptable cell viability with reasonable transfection efficiency and was used in 

















3.2 In vitro Studies 
 
3.2.1 Static Induction of Human Insulin by Glucose and Zinc 
Hepatocytes electroporated with p3MTChins were tested for glucose and 
zinc inducibility of the bifunctional promoter. Levels of human insulin secretion 
were measured in hepatocytes exposed to increasing glucose concentrations 
(2.5, 10, 15 and 25 mM) (Figure 3). Increasing ambient glucose concentration 
from 2.5 mM to 25 mM glucose increased insulin secretion by 3-fold (53.1±1.6 




























Figure 3. Glucose-induced insulin secretion 
 
Human insulin concentrations in 24h conditioned media of p3MTChins-
electroporated hepatocytes cultured in increasing glucose concentrations (2.5, 





Similarly, hepatocytes were exposed to increasing levels of zinc (5, 10, 20 
and 60 µM), in the presence of 25 mM glucose, to measure the levels of insulin 
secreted (Figure 4). Like glucose stimulation, increasing zinc concentrations 
increased insulin secretion from transfected hepatocytes with 60 µM zinc 
producing a 2.3-fold increase in insulin secretion compared to 5 µM zinc 

























Figure 4. Zinc-induced insulin secretion 
Human insulin concentrations in 24h conditioned media of p3MTChins-
electroporated hepatocytes cultured in increasing zinc concentrations (5, 10, 20 











3.2.2 Kinetics of Glucose-induced Insulin Secretion 
We characterized the kinetics of inducible insulin secretion of primary 
hepatocytes transfected with p3MTChins by measuring the amount of insulin 
secreted at various time points (5, 10 and 60 minutes) after exposure to 25 mM 
glucose. De-induction was measured in a parallel series of plates that was 
returned to 2.5 mM glucose after 60 minutes exposure to 25 mM glucose. Insulin 
secretion was measured at 20 and 60 minute time points in the de-induction 
plates (Figure 5). 
On exposure to the 25 mM glucose stimulus, insulin secretion by the 
hepatocytes rose and by 60 minutes, the insulin concentration was 4-fold above 
baseline (defined as the mean insulin concentration 20 minutes before exposure 
to 25 mM glucose) (145.3±10.7 pM vs. 34.6±2.7 pM, p=0.003). When returned to 
2.5 mM glucose, insulin secretion by the hepatocytes declined such that the 









































Figure 5. Kinetics of glucose-induced insulin secretion 
 
Induction of insulin secretion in hepatocytes electroporated with p3MTChins by 
25 mM glucose for 60min followed by downregulation in 2.5 mM glucose for a 























3.2.3 Transcriptional Response of Transgene 
To determine the transcriptional response of human insulin in p3MTChins 
to glucose stimulation, transgenic mRNA was assayed by RT-PCR at the same 
time points in the kinetic study above. 
 Figure 6 shows the increase in insulin mRNA levels to be concordant with 
the kinetic study of insulin secretion in Figure 5. By 10 minutes after exposure to 
25 mM glucose, the amount of insulin transcripts had risen by 1.6-fold over 
baseline. At 60 minutes after returning to 2.5 mM glucose, insulin mRNA levels 
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Figure 6. Kinetics of glucose-induced insulin mRNA expression
Induction of human insulin transcription in electroporated hepatocytes by 25 mM 
glucose followed by downregulation in 2.5 mM glucose. Insulin RNA was 
quantified by real time RT-PCR after subtracting a parallel minus-RT control and 















3.3 Animal Studies 
 
3.3.1 Induction of Diabetes 
During the planning stages of this pilot study, the literature on inducing 
diabetes with streptozotocin in non-human primates, in particular cynomolgus 
monkeys, was reviewed. It became evident that a wide range of doses of 
streptozotocin had been used with varied success in establishing diabetes. This 
had to be balanced against the development of associated serious adverse 
effects (nephrotoxicity and hepatotoxicity) that also occurred with considerable 
variability. 
 Stegall et al used a streptozotocin dose of 50 mg/kg body weight and 
reported 3 deaths from acute renal failure [151], while Litwak et al reported no 
deaths when using a dose of 30 mg/kg [152]. It should be noted that some 
monkeys required a second dose, and occasionally even a third dose, in order to 
develop diabetes in both these studies. Then in 1999, Theriault et al employed a 
single dose of 150 mg/kg and achieved a 100% success rate in inducing 
diabetes [153]. There was transient biochemical evidence of liver and renal 
dysfunction (raised AST, ALT and urea) but no deaths among the monkeys. 
 In an attempt to determine the optimal dose of streptozotocin that would 
cause diabetes with minimal toxicity in cynomolgus monkeys, Koulmanda et al 
compared 55 mg/kg (low dose) versus 100 mg/kg (high dose) of streptozotocin 
[155]. In both groups, all monkeys became diabetic, some up to one year. 
However, the high-dose animals developed elevated liver function tests, urea 
 42
and creatinine, with steatosis of the liver and tubular injury in the kidneys evident 
on histology. The low-dose animals did not develop any adverse effects and they 
concluded that a low dose of 55 mg/kg was optimal. 
 The following year, Wijkstrom and co-workers demonstrated that an even 
higher dose of 150 mg/kg could be used to induce diabetes without causing any 
deaths among the monkeys, albeit biochemical derangement of liver and renal 
function was again evident [156]. What was more impressive was that the 
monkeys could go on to receive immunosuppression without adverse effects. 
The same group then recommended administering streptozotocin based on body 
surface area (BSA) instead of weight to remove the confounding factor of age 
[157]. The dose was 1250 mg/m2 where BSA was calculated by: body 
weight0.67x12/10,000.  
Hence, it was not possible to develop a standard protocol for 
streptozotocin-induced diabetes in cynomolgus monkeys owing to the widely 
variable results of the above studies. What we could conclude was: a) either sex 
of animal could be used, b) a body weight of less than 3.5 kg is preferable, c) 
younger monkeys were better at tolerating higher streptozotocin doses, and d) 
hydration pre- and post-streptozotocin administration was important. The 
variability in diabetogenic action of streptozotocin and narrow window before the 
development of toxicity in monkeys was probably due to the genetic and ecologic 
diversity of the animals [149]. 
Our experience with the use of streptozotocin to induce diabetes in the 
course of this study is summarized in the following table: 
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Table 1. Summary of sex, streptozotocin dose administered and resultant 






Sex Streptozotocin dose Outcome 
DM1 M 1250 mg/m2 = 118.3 
mg/kg body weight 
Diabetes successfully induced 
  Died after complications of anaesthesia 
DM2 F 1250 mg/m2 = 115.1 
mg/kg body weight 
Diabetes was induced.   
However, biochemical evidence of renal 
failure appeared 4 days after streptozotocin.  
Placed in intensive care and full supportive 
care given: treated with subcutaneous insulin 
injections and hydration, sodium bicarbonate 
infusion to correct acidosis, intravenous 
antibiotics, tube feeding and intravenous 
furosemide.  Generalised seizure on 6th day 
after streptozotocin. Euthanasia was advised 
on the 7th day because of significant 
neurological deterioration. Autopsy revealed 
florid acute tubular necrosis.  
 
DM3 M 85/mg/kg body 
weight 
Developed diabetes. 
Received autologous hepatocyte 
transplantation resulting in partial 
improvement in hyperglycemia for 65 days. 
Thereafter, subcutaneous insulin injections 
were instituted in an attempt to achieve body 
weight gain that was ultimately unsuccessful. 
Euthanasia was advised on the 138th 
experimental day when body weight fell 
below 70% of its starting body weight (which 
was approximately 80% of its body weight 
after streptozotocin administration.) 
Autopsy showed emaciation with significant 
reduction in body fat and no other notable 
pathology in the organs examined. 
DM4/7 F 80.5/mg/kg body 
weight 









DM5 M 85.6/mg/kg body 
weight 
Developed diabetes. 
Biochemical evidence of hepatorenal toxicity 
8 days after streptozotocin prompted daily 
hydration with subcutaneous physiological 
saline (1 mg/kg body weight/hour) and daily 
subcutaneous insulin injections to control 
hyperglycemia. 
Found dead in its cage 12 days after 
streptozotocin administration.  
Autopsy findings were consistent with acute 
renal tubular necrosis, hepatic steatosis and 
interstitial pneumonia.  There were no other 
diagnostic pathological findings. 
DM6 F 85 mg/kg body 
weight 
Did not develop diabetes. 
 
DM8 M 73 mg/kg body 
weight 
Developed diabetes. This animal is assigned 
to the untreated control group of the study 
Clinically well. 
DM9 M 68 mg/kg body 
weight 
Developed diabetes. This animal has been 
assigned to the treatment group of the study. 
Clinically well. 
DM10 M 70 mg/kg body 
weight 
Developed diabetes. This animal is assigned 
to the untreated control group of the study 
Clinically well. 
DM11 M 70 mg/kg body 
weight 
Developed mild diabetes. This animal has 




 The first two monkeys, DM1 and DM2, received a streptozotocin dose 
based on their body surface area as described by Wijkstrom et al [157] (see 
above). This translated to 115–118 mg/kg. Unfortunately, DM2 developed acute 
renal failure secondary to acute tubular necrosis and deteriorated despite full 
supportive therapy necessitating euthanasia. 
 In view of this, the streptozotocin dose given was reduced to 80-85% of 
the full dose that was calculated (based on the body surface area) for the next 4 
monkeys. This translated to 80-85 mg/kg. DM3 successfully became diabetic and 
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went on to undergo autologous hepatocyte transplantation that partially corrected 
the severe hyperglycaemia. However, it became emaciated which ultimately 
required euthanasia. Autopsy did not reveal any specific pathology. DM5 also 
became diabetic but developed biochemical evidence of hepatorenal toxicity. It 
was found dead in its cage 12 days later probably due to acute renal failure. 
DM4/7 and DM6 did not develop diabetes despite receiving 2 doses of 
streptozotocin each. Interestingly, both animals were female. They did not 
undergo further procedures and were returned to the husbandry unit. 
Faced with the severe hyperglycaemia that developed in DM3 and the 
death of DM5 from renal failure, the streptozotocin dose was reduced further in 
the subsequent 4 monkeys and only males were used. DM8, DM9, DM10 and 
DM11 received a dose of 70% of that calculated by their body surface area. They 
all became diabetic, without renal failure, and all proceeded to autologous 
hepatocyte transplantation as the study proper.  
Based on this initial experience with streptozocin-induced diabetes in 
cynomolgus monkeys, we can conclude that individual monkeys have varying 
susceptibility to beta-cell ablation by streptozotocin. The dose to induce 
moderate hyperglycaemia is in the range of 65-80 mg/kg body weight. Female 
monkeys appear to be more resistant to the diabetogenic effect of streptozotocin 
than their male counterparts. Also, some degree of hepatotoxicity and 
nephrotoxicity is probably unavoidable. 
Nevertheless, we were able to induce diabetes in 8 out of 10 monkeys. 
The average values of the intravenous glucose tolerance tests of these 8 animals 
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before and after streptozotocin treatment are shown in Figure 7. Post-
streptozotocin, the monkeys had higher glucose levels when fasted and 
throughout the glucose tolerance tests. The rate of glucose clearance in these 
























Figure 7. Induction of diabetes with streptozotocin 
Intravenous glucose tolerance tests were performed before and after STZ 
treatment. After an overnight fast, 0.5 g/kg glucose was administered and blood 
sampled at 1, 3, 5, 10, 20, 30, 45 and 60 minutes later for blood glucose levels. 






Further evidence of successful islet ablation was provided by histological 
assessment of pancreata removed at autopsy. In the micrographs below, the 
pancreas of diabetic monkeys DM8 and DM10 showed absence of insulin-
positive cells in the islets while in the pancreas of DM4, which did not become 
















 DM4 Not diabetic 
   
 DM8 Diabetic 
 
 DM10 Diabetic 
 
Figure 8. Absence of insulin-positive cells in pancreas of diabetic monkeys 
 
Pancreata harvested at autopsy were stained for insulin. Non-diabetic monkey 
DM4 had insulin-positive cells (arrowed) in the islets while diabetic monkeys DM8 
and DM10 did not.  
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3.3.2 Hepatocyte Transplantation 
In the study proper, two monkeys, DM8 and DM10, were transplanted with 
autologous hepatocytes that were mock electroporated to serve as controls, 
while another two monkeys, DM9 and DM11, were transplanted with autologous 
hepatocytes electroporated with p3MTChins as the treated group. 
 The characteristics of these 4 subject monkeys are summarized in the 
table below: 
 
Table 2. Characteristics of 4 diabetic monkeys that underwent liver resection and 
hepatocyte transplantation 
 













DM8 M 3.95 73 30% left lobe 20 million Control 
DM9 M 4.63 68 50% left lobe 29 million Treated 
DM10 M 4.77 70 30% left lobe 18 million Control 
DM11 M 5.00 70 40% left lobe 19 million Treated 
  
The outcome of hepatocyte transplantation was assessed by daily fasting 
blood glucose levels and insulin requirements, intravenous glucose tolerance 






3.3.2.1 Blood Glucose Levels and Insulin Requirements 
 Fasting blood glucose levels were measured in the morning before 
feeding the animals. Exogenous insulin was administered if the blood glucose 
levels were high (>300mg/dl) to avoid ketoacidosis developing. The figures below 







































Average post-transplant daily insulin dose = 7.3 units
 
Figure 9a 












































Average post-transplant daily insulin dose = 0 units
 
Figure 9c 



















Figure 9a-d. Daily fasting blood glucose levels of 4 monkeys in study 
 
Capillary blood glucose was measured in the morning before feeding by lancing 
the digits or abdominal wall 
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 Overall, no trend can be found in these measurements but it should be 
noted that in the treated animals, the fasting blood glucose levels never 
exceeded 500 mg/dl despite no insulin being administered during the post-
transplant period. However, DM11 was only mildly diabetic before the transplant. 
This partial correction in hyperglycaemia in DM9 was present for 113 days until 
the study was terminated. However, there was a slow deterioration in the effect. 
 In contrast, the control group, DM8 and DM10, had blood glucose levels 
occasionally exceeding 500 mg/dl, even though the average daily insulin 
requirements post-transplant were 7.3 and 6.9 units respectively. 
 
3.3.2.2 Intravenous Glucose Tolerance Tests (IVGTT) 
In order to better assess the outcome of hepatocyte transplantation, 
IVGTTs were performed on the animals at 3 stages during the study, namely 
normal (pre-STZ), diabetic (post-STZ), and post-transplant. After an overnight 
fast, a glucose load of 0.5 g/kg was administered to the animals intravenously. 
Blood was then sampled at 1, 3, 5, 10, 20, 30, 45 and 60 minutes thereafter to 



































































































































Figure 10a-d. Blood glucose IVGTT curves of all 4 monkeys in study
 
Intravenous glucose tolerance tests were performed pre-STZ, post-STZ and 
post-hepatocyte transplant. After an overnight fast, 0.5 g/kg glucose was 
administered and blood sampled at 1, 3, 5, 10, 20, 30, 45 and 60 minutes later 
for blood glucose levels. 
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Figure 11. Area under the curve for blood glucose IVGTT curves  
 
IVGTT was performed at normal (pre-STZ), diabetic (post-STZ) and post-
transplant stages during the study. AUC was calculated with the Trapezoidal 
Rule 
 
In both controls, the post-transplant IVGTT curves followed that of the 
diabetic (pre-transplant) state which confirmed the mock electroporated 
hepatocytes status and islet ablation by streptozotocin. In the treated group, DM9 
showed a post-transplant IVGTT curve which returned to the normal (pre-diabetic 
state) suggesting the hepatocytes electroporated with p3MTChins were able to 
function as surrogate islets to a certain extent. However, this was not seen in 
DM11 as it was only rendered mildly diabetic and all 3 IVGTT curves were the 
same. 
Further evidence came from calculating the area under curve (AUC) for 
the IVGTT curves, as shown above, where the controls had higher glucose AUCs 
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post-transplant compared to the diabetic period, while the treated animals had 
lower post-transplant glucose AUCs. 
 

































































































Figure 12a-d. Insulin IVGTT curves of all 4 monkeys in study
 
Intravenous glucose tolerance tests were performed pre-STZ, post-STZ and 
post-hepatocyte transplant. After an overnight fast, 0.5 g/kg glucose was 
administered and blood sampled at 1, 3, 5, 10, 20, 30, 45 and 60 minutes later 
for insulin levels. 
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Figure 13. Area under the curve for insulin IVGTT curves  
 
IVGTT was performed at normal (pre-STZ), diabetic (post-STZ) and post-




In terms of insulin release during the IVGTT, again the controls had post-
transplant curves similar to that of the diabetic state. This goes to show again 
that neither the mock electroporated hepatocytes nor the native islets were 
producing insulin. 
 As for the 2 treated animals, both showed an increase in insulin release 
during the IVGTT post-transplant compared to the diabetic phase, although it 
was not as high as the normal non-diabetic phase. This provides more evidence 
that the treated hepatocytes were able to respond to a change in ambient 
glucose levels and secrete insulin. 
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The AUC for insulin release during the IVGTTs confirms that the treated 
animals had higher insulin levels, in response to the glucose load, post-transplant 
compared to the diabetic state. In contrast, this was not seen in the controls. 
 
3.3.3 Liver and Renal Function 
In all 4 animals, blood was sampled at regular intervals to conduct 


















































































































































































Figure 14a-d. Liver function tests of 4 study animals 
 
Blood was sampled at regular intervals for measurement of liver function. ALT – 
alanine aminotransferase, Alk Phos – alkaline phosphatase 
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Figure 15a-d. Renal function tests of all 4 study monkeys 
 




In the controls, liver AST and alkaline phospatase rose post-STZ 
treatment, this was not seen in the treated group. Following liver resection and 
hepatocyte transplantation, the AST and alkaline phosphatase in both groups 
increased further which was to be expected. However, fulminant liver failure, with  
grossly elevated liver enzymes and associated jaundice, anasarca, bleeding 
diathesis and encephalopathy, never developed in any of the animals.    
Renal function, in terms of blood urea and creatinine levels, worsened 
after streptozotocin exposure in all animals reflecting its nephrotoxic effects. 
However, in 3 out of 4 animals, namely DM8, DM9 and DM11, their renal function 
continued to slowly deteriorate after hepatocyte transplant. This may have been 














CHAPTER 4: DISCUSSION 
 
4.1 Overview 
The objectives of this project were: 1) to optimize a method of harvesting, 
isolating and transfecting primary primate hepatocytes with a plasmid construct 
encoding human proinsulin cDNA, 2) to develop a reliable protocol to induce 
diabetes in monkeys using streptozotocin, and 3) to compare engraftment and 
functional effects of transplanted engineered autologous hepatocytes in 
streptozotocin-diabetic monkeys. 
 For the first objective, a technique that minimized warm ischaemia time 
was employed successfully to partially resect a liver lobe in anaesthetized 
monkeys for hepatocyte harvest. Subsequently, hepatocyte isolation was carried 
out using a modified Bumgardner protocol which produced good viability. The 
Amaxa Nucleofector system apparatus was used to transfect the isolated primary 
hepatocytes obtained. As there was no recommended program setting available 
for primate hepatocytes, various settings were assessed with a reporter plasmid 
and program H22 was found to produce reasonable transfection efficiency with 
acceptable cell viability (Figure 2) and was used for all future transfections. 
 Our in vitro results demonstrate successful transfection of primary primate 
hepatocytes with the plasmid construct p3MTChins. In static studies, inducibility 
of the bifunctional promoter of the plasmid construct by increasing glucose and 
zinc concentrations was evidenced by a corresponding increase in insulin 
secretion. Subsequent kinetic studies showed that both insulin mRNA expression 
 67
and insulin secretion were increased with exposure to high glucose 
concentrations and then decreased when glucose concentrations were reduced. 
Hence, the engineered hepatocytes were able to produce insulin in a regulated 
manner. 
 After a trial of high dose streptozotocin, we settled on a dose of 875  
mg/m2 where BSA was calculated by: body weight0.67x12/10,000. This dose was 
found to reliably induce diabetes in male monkeys with only transient biochemical 
derangement of liver and renal function. Intravenous glucose tolerance tests 
before and after streptozotocin treatment confirmed the development of diabetes 
in the 8 animals successfully induced. They had higher blood glucose levels 
throughout the tests post-streptozotocin and a lower K-value of glucose 
clearance. Histology showed absence of insulin staining in pancreata of diabetic 
monkeys. 
 As regards the third objective, our animal study proper on 4 monkeys 
showed that the treated animals had overall lower fasting blood glucose levels 
and did not require exogenous insulin therapy to achieve this compared to the 
controls. Intravenous glucose tolerance tests at various stages of the study 
showed the treated animals having post-transplant curves of blood glucose 
similar to that of the non-diabetic state and post-transplant curves of insulin 
higher than that of the diabetic state. AUC levels of glucose were reduced and 
insulin increased post-transplant in the treated animals but the reverse was seen 
in the controls. 
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4.2 Isolation and Electroporation of Primary Primate Hepatocytes 
Autologous hepatocytes present a renewable source for a cell-based 
approach to diabetes treatment. In our approach, less than 13% of the total 
volume of the liver was resected for hepatocyte isolation, and this is within the 
regenerative capacity of the liver [124]. There was only transient biochemical 
evidence of liver dysfunction and no progression to liver failure. This overcomes 
the problem of donor scarcity as seen in allogeneic islet transplantation. 
Furthermore, using autologous hepatocytes obviates the need for long term 
immunosuppression and they are also not targets for recurrent autoimmune 
destruction [125] or increased beta cell apoptosis [159] of types 1 and 2 diabetes, 
respectively. 
We chose to use electroporation to transfect the isolated hepatocytes with 
a nonviral vector of human proinsulin cDNA for several reasons: it is rapid, 
simple, and produced reasonable efficiency. Isolation and transfection of 
autologous hepatocytes was performed in a reasonably short turnaround time of 
2-3 hours which allowed us to transplant the engineered hepatocytes in the same 
period of general anaesthesia as the liver resection. This would prove more 
clinically acceptable as it would mean a single procedure and reduced 
anaesthetic exposure to the patient.  
As we did not perform ex vivo viral transduction and culture of primary 
hepatocytes, we avoided the attendant risks of producing chromosomal 
aberrations [160, 161] or co-implanting free viral particles with adverse 
immunogenic or genotoxic effects resulting in oncogenicity. In addition, plasmid 
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vectors are cheaper to produce, have low toxicity and immunogenicity, and are 
non-pathogenic compared to viral vectors. Although, in our study, we did not 
quantitate average plasmid copy number in transfected hepatocytes, others have 
reported on the transfer of vectors in high copy number (up to 800) by 
electroporation [162]. Furthermore, durable retention of plasmid vectors by non-
mitotic hepatocytes [163] would sustain the therapeutic effects of the engineered 
hepatocytes and, again, make this approach more clinically acceptable. 
 
4.3 Preclinical Model of Diabetes Mellitus 
We elected to assess our approach in a primate diabetes model as 
nonhuman primates have evolutionary proximity to humans and exhibit >95% 
homology at the genome level [145]. Previous attempts at gene- and cell-based 
diabetes treatment that were effective in murine models have not been 
successfully adapted to large animals. We felt utilizing a primate model would 
move our findings a step closer to clinical application. 
Induction of diabetes in cynomolgus macaques with streptozotocin was 
not that straightforward. Success with high dose streptozotocin reported by 
others [156, 157] was not reproducible in our study. We had to reduce the dose 
of streptozotocin to 70% of that described and this reliably induced diabetes with 
only transient derangement in liver and renal function. 
A likely explanation for the variability in susceptibility to streptozotocin and 
the development of toxic effects is that nonhuman primates tend to be outbred 
and wild-caught unlike commonly used species of small laboratory animals. They 
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are thus genetically diverse and disparate in terms of body weight, diet and 
general health [149]. 
 
4.4 Engraftment and Function of Transplanted Engineered Hepatocytes 
We chose to transplant engineered hepatocytes directly into the liver 
parenchyma instead of infusion via the portal vein. Portal vein-infused 
hepatocytes are prone to destruction by blood macrophages [138] and often also 
lead to intraportal thrombosis and pulmonary embolism with infarction [134]. In 
contrast, hepatocytes implanted directly into the liver parenchyma did not 
distribute to other organs and integrated normally into liver lobules [140]. 
Therapeutic efficacy of transplanted hepatocytes was demonstrated by the 
overall lower fasting blood glucose levels in treated monkeys and without the 
need for exogenous insulin therapy to maintain it. More evidence came from 
challenge tests in the form of intravenous glucose tolerance tests - the treated 
animals having lower blood glucose and higher secreted insulin levels.  
Our attempts to immunostain liver sections from transplanted sites of 
treated animals using an antibody against human insulin were unsatisfactory 
because of the known cross-reactivity between human and monkey insulin. We 
were unable to locate a source of anti-human C-peptide antibody that might have 
provided clear evidence of transgenic insulin secretion in implanted hepatocytes. 
However, haematoxylin and eosin-stained sections of the transplanted sites 
showed entirely normal liver lobular architecture without evidence of fibrosis or 
inflammation.  
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4.5 Limitations of Current Study 
Being a pilot study, the number of animals used was too small to 
demonstrate any statistical significance and the follow-up period was too short to 
assess long term engraftment and function. Nevertheless, this project was able 
to demonstrate proof of concept in using engineered autologous hepatocytes as 
cell-based treatment for diabetes mellitus in a preclinical model. 
 Obtaining hepatocytes by laparotomy and partial liver resection may be 
deemed too invasive by some. Laparoscopic resection may be a way of 
overcoming this. Optimising hepatocyte isolation further will allow for a smaller 
wedge of the liver to be resected. 
 
4.6  Future Work 
Having demonstrated proof of concept, the next step would be to repeat the 
study in a larger cohort of monkeys. Varying the number of cells transplanted and 
assessing their therapeutic responses should also be studied in order to 
establish a treatment protocol. A longer period of follow-up and measurement of 
target organ injury in terms of retinopathy, nephropathy and neuropathy would 
also be ideal in the larger study to extend the assessment of the therapeutic 






4.7     Conclusions 
• A moderate streptozotocin dose reliably induces diabetes in cynomolgus 
macaques with transient biochemical evidence of liver and renal 
dysfunction. 
• Autologous hepatocytes transfected with a human proinsulin cDNA 
construct are able to behave as surrogate beta cells in the treatment of a 
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